Netazepide: further clinical studies

Phase 32019-08-15T08:33:14+00:00

Phase 3 study of netazepide in g-NETs

We plan to do a multicentre, randomised study of netazepide and placebo (ratio 6:1) in 210 patients with CAG and multiple g-NETs in Europe, USA, and possibly China and Japan (Figure 13). Centres of Excellence of the European and North American Neuroendocrine Tumour Societies (ENETS and NANETS, respectively) have agreed to participate (Figure 14). The NET Patient Foundation and the Pernicious Anaemia Society, organisations with members who have g-NETs, have also agreed to support the study.

The European Medicines Agency has approved in principle a single pivotal study. An IND is in place, and an FDA end-of-phase 2 meeting is planned. The study is on schedule to start fourth quarter 2020 and to last 3 years.

Figure 13. Design of proposed study of netazepide in 210 patients

Design of proposed phase 3 study of netazepide in 210 patients

Figure 14. Centres with g-NETs patients in Europe, USA, China and Japan, and patient organisations

Centres with g-NETs patients in Europe, USA, China and Japan, and patient organisations

Zollinger Ellison syndrome

Patients with the rare Zollinger Ellison syndrome have a gastrin-secreting tumour called a gastrinoma that grows mainly in the pancreas or gut and causes hypergastrinaemia, growth of ECL cells, and in some patients, formation of g-NETs1. Up to 50% of those g-NETs become malignant, especially in the 20–30% of patients with the multiple endocrine neoplasia (MEN-1) gene. But, unlike CAG patients, patients with a gastrinoma have an intact stomach lining, which therefore responds to hypergastrinaemia by producing excessive acid and thereby severe ulcers. Netazepide blocks gastric acid production as well as ECL-cell growth, which makes it an ideal treatment for Zollinger Ellison syndrome. Therefore, we plan a separate clinical trial of netazepide in patients with Zollinger Ellison g-NETs.


  1. Dockray GJ, Moore A, Varro A, Pritchard DM: Gastrin receptor pharmacology. Curr Gastroenterol Rep 2012; 14: 453–459.
  2. Dimaline R, Varro A: Novel roles of gastrin. J Physiol (Lond) 2014; 592: 2951–2958.
  3. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis: pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10: 529–541.
  4. Cheung K, Chan E, Wong A, Chen L, Wong I, Leung W. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018; 67: 28–35.
  5. Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open 2017; 7: e017739
  6. Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 2013; 37: 375–382.
  7. Sørdal Ø, Waldum H, Nordrum I, Boyce M, Bergh K, Munkvold B, Qvigstad G. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2013; 18: 397–405.
  8. Vogiatzi P, Cassone M, Luzzi I, Lucchetti C, Otvos L, Giordano A. Helicobacter pylori as a class I carcinogen: physiopathology and management strategies. Cell Biochem 2007; 102: 264–273.
  9. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas P. Systematic review: the effects of long‐term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649–663.
  10. Ashida K, Sakurai Y, Hori T, Kudou K, Nishimura A, Hiramatsu N, UMegaki E, Iwakiri K. Randomised clinical trial: vonoprazan, a novel potassium competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Thar 2016; 43: 240–251.
  11. Graham D, Dore M. Update on the use of vonoprazan: a competitive acid blocker. Gastroenterology 2018; 154: 462–466.
  12. Calvete O, Reyes J, Zuñiga S, Paumard-Hernández B, Fernández V, Bujanda L, Rodriguez-Pinilla MS, Palacios J, Heine-Suñer D, Banka S et al. Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Hum Mol Genet 2015, 24: 2914–2922.
  13. Winbo A, Sandström O, Palmqvist R, Rydberg A. Iron-deficiency anaemia, gastric hyperplasia, and elevated gastrin levels due to potassium channel dysfunction in the Jervell and Lange-Nielsen Syndrome. Cardiol Young 2013; 23: 325–334.
  14. Jianu C, Fossmark R, Viset T, Qvigstad G, Sørdal Ø, Mårvik R, Waldum H: Gastric carcinoids after long‐term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644–649.
  15. Jianu CS, Lange OJ, Viset T, Qvigstad G, Martinsen TC, Fougner R, Kleveland PM, Fossmark R, Hauso Ø, Waldum HL: Gastric neuroendocrine carcinoma after long-term use of a proton pump inhibitor. Scand J Gastroenterol 2012; 47: 64–67.
  16. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P. ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology 2012; 95: 74–87.
  17. Kulke M, Anthony L, Bushnell D et al. NANETS treatment guidelines-well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735–752.
  18. Takinami Y, Yuki H, Nishida A, Akuzawa S, Uchida A, Takemoto Y, Ohta M, Satoh M, Semple G, Miyata K. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997; 11: 113–120.
  19. Boyce M, Lloyd KA, Pritchard DM. Potential clinical indications for a gastrin/CCK2 receptor antagonist. Curr Opin Pharmacol 2016; 31: 68–75.
  20. Chen D, Zhao C-M, Norlén P, Björkqvist M, Ding X-Q, Kitano M, Håkanson R. Effect of CCK2 receptor blockade on rat ECL cells. Cell Tissue Res 2000; 299: 81–95.
  21. Martinsen TC, Kawase S, Håkanson R, Torp SH, Fossmark R, Qvigstad G, Sandvik AK, Waldum HL. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 2003; 24: 1887–1896.
  22. Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012; 36: 181–9.
  23. Boyce M, Warrington S, Black J. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 689–698.
  24. Boyce M, Dowen S, Turnbull G, Berg F, Zhao CM, Chen D, Black J. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia: a double-blind trial in healthy subjects. Br J Clin Pharmacol 2015; 79: 744–755.
  25. Boyce M, Thomsen L. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol 2015; 50: 550–559.
  26. Boyce M, Moore AP, Sagatun L, Parsons B, Varro A, Campbell F, Fossmark R, Waldum HL, Pritchard DM. Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol 2017; 83: 466–475.
  27. Moore AR, Parsons BN, Boyce MJ, Rainbow L, Fang Y, Varro A, Hall N, Pritchard DM. Identification of Potential Biomarkers of Netazepide (YF476) Treatment of Type I Gastric neuroendocrine tumours. Gastroenterology 2015; 148:  S-342.
  28. Lloyd KA, Moore AR, Parsons BN, O’Hara A, Boyce M, Dockray GJ, Varro A, Pritchard DM: Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip. Oncotarget 2016; 19: 45462–45478.
  29. Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci 2019; 44: 141–152.
  30. Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 2017; 4: 167–185.